Paul M Stewart

List of Publications by Year
in descending order

93	8,813	76326 40	48315 88
papers	citations	h-index	g-index

95	95	95	8507
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Regulation of 11Î²-HSD1 by GH/IGF-1 in key metabolic tissues may contribute to metabolic disease in GH deficient patients. Growth Hormone and IGF Research, 2022, 62, 101440.	1.1	3
2	Oral 11Î²-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial. European Journal of Endocrinology, 2022, 186, 441-455.	3.7	12
3	Effect of AZD4017, a Selective 11Î²-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2026-2035.	3.6	4
4	The Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2377-2388.	3.6	18
5	Increased systemic and adipose 11Î²-HSD1 activity in idiopathic intracranial hypertension. European Journal of Endocrinology, 2022, 187, 323-333.	3.7	11
6	Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 814-825.	3.6	8
7	11Î²HSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 174-187.	3.6	39
8	Maternal iodine status in a multiâ€ethnic UK birth cohort: Associations with child cognitive and educational development. Paediatric and Perinatal Epidemiology, 2021, 35, 236-246.	1.7	9
9	Prenatal and Postpartum Maternal Iodide Intake from Diet and Supplements, Urinary Iodine and Thyroid Hormone Concentrations in a Region of the United Kingdom with Mild-to-Moderate Iodine Deficiency. Nutrients, 2021, 13, 230.	4.1	10
10	Evaluating tertiary adrenal insufficiency in rheumatology patients on longâ€term systemic glucocorticoid treatment. Clinical Endocrinology, 2021, 94, 361-370.	2.4	13
11	Environmental Pollution, Climate Change, and a Critical Role for the Endocrinologist. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3381-3384.	3.6	1
12	The contribution of serum cortisone and glucocorticoid metabolites to detrimental bone health in patients receiving hydrocortisone therapy. BMC Endocrine Disorders, 2020, 20, 154.	2.2	3
13	Maternal iodine status in a multi-ethnic UK birth cohort: associations with autism spectrum disorder. BMC Pediatrics, 2020, 20, 544.	1.7	3
14	Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. Cmaj, 2020, 192, E295-E301.	2.0	43
15	Maternal iodine status, intrauterine growth, birth outcomes and congenital anomalies in a UK birth cohort. BMC Medicine, 2020, 18, 132.	5.5	16
16	11Î²-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. Brain Communications, 2020, 2, fcz050.	3.3	46
17	Our Response to COVID-19 as Endocrinologists and Diabetologists. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1299-1301.	3.6	89
18	Adrenal Incidentaloma. Endocrine Reviews, 2020, 41, 775-820.	20.1	144

#	Article	IF	Citations
19	Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy. Clinical Endocrinology, 2019, 90, 3-14.	2.4	23
20	Dose Dependency of Iatrogenic Glucocorticoid Excess and Adrenal Insufficiency and Mortality: A Cohort Study in England. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3757-3767.	3.6	48
21	Increased central adiposity and decreased subcutaneous adipose tissue 11Î²â€hydroxysteroid dehydrogenase type 1 are associated with deterioration in glucose toleranceâ€"A longitudinal cohort study. Clinical Endocrinology, 2019, 91, 72-81.	2.4	9
22	Modified-Release Hydrocortisone: Is It Time to Change Clinical Practice?. Journal of the Endocrine Society, 2019, 3, 1150-1153.	0.2	23
23	Maternal Iodine Status and Associations with Birth Outcomes in Three Major Cities in the United Kingdom. Nutrients, 2019, 11, 441.	4.1	24
24	Apparent Mineralocorticoid Excess. , 2019, , 638-643.		4
25	The Short Synacthen Test and Its Utility in Assessing Recovery of Adrenal Function in Patients With Central Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 17-20.	3.6	6
26	MON-447 Impact Of Cortisone And Glucocorticoid Metabolites On Bone Turnover Markers in Male Patients With Hypopituitarism. Journal of the Endocrine Society, 2019, 3, .	0.2	0
27	Immediate versus modified release hydrocortisone in mitotaneâ€treated patients with adrenocortical cancer. Clinical Endocrinology, 2017, 86, 499-505.	2.4	5
28	11Î²-HSD1 Modulates the Set Point of Brown Adipose Tissue Response to Glucocorticoids in Male Mice. Endocrinology, 2017, 158, 1964-1976.	2.8	26
29	Health Care Burden in Patients With Adrenal Insufficiency. Journal of the Endocrine Society, 2017, 1, 512-523.	0.2	16
30	25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 exert distinct effects on human skeletal muscle function and gene expression. PLoS ONE, 2017, 12, e0170665.	2.5	65
31	Male 11Î²-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease. Endocrinology, 2016, 157, 3493-3504.	2.8	16
32	Glucocorticoids and 11Î²-HSD1 are major regulators of intramyocellular protein metabolism. Journal of Endocrinology, 2016, 229, 277-286.	2.6	30
33	Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4843-4850.	3.6	68
34	11Î²-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation. Journal of Pathology, 2016, 240, 472-483.	4.5	38
35	Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes and Endocrinology,the, 2016, 4, 569-576.	11.4	151
36	High throughput LCâ€"MS/MS method for the simultaneous analysis of multiple vitamin D analytes in serum. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1014, 56-63.	2.3	75

#	Article	IF	Citations
37	Gender-Specific Differences in Skeletal Muscle 11Î²-HSD1 Expression Across Healthy Aging. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2673-2681.	3.6	67
38	Differential glucocorticoid metabolism in patients with persistent versus resolving inflammatory arthritis. Arthritis Research and Therapy, 2015, 17, 121.	3.5	12
39	Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax, 2015, 70, 617-624.	5.6	258
40	Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol. European Journal of Endocrinology, 2015, 173, 633-642.	3.7	116
41	The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure. European Journal of Endocrinology, 2015, 173, 583-593.	3.7	13
42	Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clinical Endocrinology, 2015, 82, 2-11.	2.4	93
43	TNFÎ± regulates cortisol metabolism in vivo in patients with inflammatory arthritis. Annals of the Rheumatic Diseases, 2015, 74, 464-469.	0.9	17
44	11Î²-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2482-91.	7.1	225
45	Saving lives of patients with adrenal insufficiency: a panâ€<scp>E</scp>uropean initiative?. Clinical Endocrinology, 2014, 80, 319-321.	2.4	21
46	Longitudinal changes in glucocorticoid metabolism are associated with later development of adverse metabolic phenotype. European Journal of Endocrinology, 2014, 171, 433-442.	3.7	24
47	Inhibition of 11Î²-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 406-416.	11.4	98
48	Saving lives of patients with adrenal insufficiency: a pan-European initiative?. , 2014, 80, 319.		1
49	11Î²-Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects. Endocrine Reviews, 2013, 34, 525-555.	20.1	152
50	Effects of Nutritional Supplementation during Pregnancy on Early Adult Disease Risk: Follow Up of Offspring of Participants in a Randomised Controlled Trial Investigating Effects of Supplementation on Infant Birth Weight. PLoS ONE, 2013, 8, e83371.	2.5	6
51	What happens to clinical training fellows? A retrospective study of the 20â€...years outcome of a Medical Research Council UK cohort. BMJ Open, 2012, 2, e001792.	1.9	8
52	Mortality and pituitary disease. Annales D'Endocrinologie, 2012, 73, 81-82.	1.4	7
53	Outcome of Cushing's Disease following Transsphenoidal Surgery in a Single Center over 20 Years. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1194-1201.	3.6	130
54	Inflammatory regulation of glucocorticoid metabolism in mesenchymal stromal cells. Arthritis and Rheumatism, 2012, 64, 2404-2413.	6.7	43

#	Article	IF	Citations
55	Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3775-3784.	3.6	369
56	Cerebrospinal Fluid Corticosteroid Levels and Cortisol Metabolism in Patients with Idiopathic Intracranial Hypertension: A Link between 11Î²-HSD1 and Intracranial Pressure Regulation?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5348-5356.	3.6	84
57	Mortality in Patients with Pituitary Disease. Endocrine Reviews, 2010, 31, 301-342.	20.1	331
58	Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ: British Medical Journal, 2010, 341, c2701-c2701.	2.3	257
59	Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). Journal of Steroid Biochemistry and Molecular Biology, 2010, 121, 496-504.	2.5	353
60	Selective Inhibitors of 11Â-Hydroxysteroid Dehydrogenase Type 1 for Patients With Metabolic Syndrome: Is the Target Liver, Fat, or Both?. Diabetes, 2009, 58, 14-15.	0.6	31
61	3 Rationale for treatment and therapeutic options in Cushing's disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, S15-S22.	4.7	24
62	The low-dose corticotropin-stimulation test revisited: the less, the better?. Nature Clinical Practice Endocrinology and Metabolism, 2009, 5, 68-69.	2.8	10
63	Can licorice lick colon cancer?. Journal of Clinical Investigation, 2009, 119, 760-763.	8.2	21
64	The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1526-1540.	3.6	2,131
65	Reduced Glucocorticoid Production Rate, Decreased 5Â-Reductase Activity, and Adipose Tissue Insulin Sensitization After Weight Loss. Diabetes, 2008, 57, 1536-1543.	0.6	79
66	Modulation of 11Î²-Hydroxysteroid Dehydrogenase (11Î²HSD) Activity Biomarkers and Pharmacokinetics of PF-00915275, a Selective 11Î²HSD1 Inhibitor. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 550-556.	3.6	86
67	11Î²-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function. Journal of Biological Chemistry, 2007, 282, 27030-27036.	3.4	48
68	Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. Arthritis Research and Therapy, 2006, 8, R108.	3.5	79
69	Tissue-specific Cushingâ€™s syndrome uncovers a new target in treating the metabolic syndrome â€“ 11Î²-hydroxysteroid dehydrogenase type 1. Clinical Medicine, 2005, 5, 142-146.	1.9	24
70	Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. European Journal of Endocrinology, 2003, 149, 163-168.	3.7	94
71	Late-Onset Apparent Mineralocorticoid Excess Caused by Novel Compound Heterozygous Mutations in the HSD11B2 Gene. Hypertension, 2003, 42, 123-129.	2.7	57
72	Glucocorticoid Regulation of P450 Aromatase Activity in Human Adipose Tissue: Gender and Site Differences. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1327-1336.	3.6	15

#	Article	IF	Citations
73	Cortisol metabolism and the role of 11Î²-hydroxysteroid dehydrogenase. Best Practice and Research in Clinical Endocrinology and Metabolism, 2001, 15, 61-78.	4.7	129
74	Modulation of 11Î²-Hydroxysteroid Dehydrogenase Isozymes by Proinflammatory Cytokines in Osteoblasts: An Autocrine Switch from Glucocorticoid Inactivation to Activation. Journal of Bone and Mineral Research, 2001, 16, 1037-1044.	2.8	211
75	Expression of 11Î²-Hydroxysteroid Dehydrogenase Isoenzymes in the Human Pituitary: Induction of the Type 2 Enzyme in Corticotropinomas and Other Pituitary Tumors. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2728-2733.	3.6	70
76	Extrarenal Expression of 25-Hydroxyvitamin D₃-1Î±-Hydroxylase¹. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 888-894.	3.6	728
77	Therapeutic patenting for glucocorticoid-induced osteoporosis. Expert Opinion on Therapeutic Patents, 2000, 10, 847-857.	5.0	0
78	Carbenoxolone effects in congenital adrenal hyperplasia. Clinical Endocrinology, 2000, 52, 246-247.	2.4	5
79	Constitutive Expression of 25-Hydroxyvitamin D3-1Î±-Hydroxylase in a Transformed Human Proximal Tubule Cell Line: Evidence for Direct Regulation of Vitamin D Metabolism by Calcium*. Endocrinology, 1999, 140, 2027-2034.	2.8	123
80	Cortisol Metabolism in Human Obesity: Impaired Cortisoneâ†'Cortisol Conversion in Subjects with Central Adiposity1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1022-1027.	3.6	356
81	Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LARÂ®). Clinical Endocrinology, 1999, 50, 295-299.	2.4	40
82	The short Synacthen test: is less best?. Clinical Endocrinology, 1999, 51, 151-152.	2.4	15
83	Constitutive Expression of 25-Hydroxyvitamin D3-1Â-Hydroxylase in a Transformed Human Proximal Tubule Cell Line: Evidence for Direct Regulation of Vitamin D Metabolism by Calcium. Endocrinology, 1999, 140, 2027-2034.	2.8	31
84	Differentiation of Adipose Stromal Cells: The Roles of Glucocorticoids and 11Â-Hydroxysteroid Dehydrogenase. Endocrinology, 1999, 140, 3188-3196.	2.8	68
85	â€˜The fat lady singsâ€™, but what is she telling us?. Clinical Endocrinology, 1998, 49, 9-10.	2.4	3
86	Differential Expression of Nuclear 11Â-Hydroxysteroid Dehydrogenase Type 2 in Mineralocorticoid Receptor Positive and Negative Tissues. Endocrinology, 1997, 138, 3077-3077.	2.8	10
87	1,25-Dihydroxyvitamin D3 Regulates Estrogen Metabolism in Cultured Keratinocytes. Endocrinology, 1997, 138, 3711-3718.	2.8	14
88	Urinary free cortisone and the assessment of 11Î²â€hydroxysteroid dehydrogenase activity in man. Clinical Endocrinology, 1996, 45, 605-611.	2.4	244
89	Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism. Clinical Endocrinology, 1995, 43, 623-629.	2.4	66
90	Apparent mineralocorticoid excess syndromes. Journal of Endocrinological Investigation, 1995, 18, 518-532.	3.3	23

#	Article	IF	Citations
91	Reproduction and the shuttle. Clinical Endocrinology, 1993, 38, 645-646.	2.4	3
92	Mineralocorticoid excess and inhibition of 11 Î²â€hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clinical Endocrinology, 1992, 37, 483-492.	2.4	176
93	Lithium Carbonate â€“ a Competitive Aldosterone Antagonist?. British Journal of Psychiatry, 1988, 153, 205-207.	2.8	14